Effect brexpiprazole augmentation for aripiprazole one-monthly on social functioning in Japanese schizophrenia: A Randomized Controlled Clinical Trial

Not Applicable

• Conditions: schizophrenia

• Registration Number: JPRN-UMIN000043577
• Lead Sponsor: Department of Neuropsychiatry, Kansai Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-01
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Serious complication Active suicidal ideations or past suicide attempts Drug or alcohol abuse Pregnant or breast-feeding females mental retardation Using of oral aripiprazole or asenapine, blonanserin Having been judged as unsuitable for the study forin other reasons by an principal investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Social Functioning Scale (SFS) from week 0 to week 52

Secondary Outcome Measures

Name	Time	Method
Remission rate, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity scale (CGI-S), Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS), UKU Side Effect Scale(UKU), Barnes Akathisia Rating Scale (BARS), Epworth Sleepness Scale(ESS), body weight, Body Mass Index, blood biochemistry, Japanese Adult Reading Test (JART), electroencephalography, Brief Assessment of Cognition in Schizophrenia (BACS), Social Cognition. Screening Questionnaire (SCSQ), Japanese version of the Questionnaire about the Process of Recovery (QPR-J), Subjective well-being under neuroleptic drug treatment short form, Japanese version (SWNS-J)